Evogene (EVGN) Reports Q3 Loss of $0.57/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- Reddit to join S&P 500 index on Aug. 18, shares leap
Evogene Reports Third Quarter 2017 Financial Results
November 22, 2017 7:00 AM ESTREHOVOT, Israel, Nov. 22, 2017 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading biotechnology company developing novel products for life science markets through the use of a unique computational predictive biology platform, announced today its financial results for the third quarter ending September 30, 2017.
Ofer Haviv, Evogene's President and CEO, stated: This is an exciting time for Evogene, as we rapidly advance the evolution of our company from a plant genomics company to a company addressing a wide... More
